New Research Shows Cannabis-Based Drug Kills 100% Of Pancreatic Cancer Cells

A new study suggests a botanical drug containing extracts of a cannabis plant has reported eliminating 100% of pancreatic cancer cells.

The plant-based drug that is an extract of the Cyathus stratus fungus in conjunction with the cannabinoid extract, killed all cancer cells without damaging any healthy cells. 

This drug has been developed by the biomedical company Cannabotech and the study was led by Professor Fuad Fares, who is a senior cancer researcher at the University of Haifa.

Under this study, the doctors used fungus as a subject for 8 years that was tested for anti-cancer efficacy and the treatment showed better anti-cancer results than a variety of other fungi tested. 

Alamy

The company believes that this plant-based drug option is comparatively cheaper and shorter as compared to the development of standard ethical drugs. 

Cannabotech has also announced that in their cell model trial they used their adapted extract and combined the cannabinoid extract and the fungi one. The results showed five times higher anti-cancer efficacy than the original extract.

The biomedical company claims to be one of the first to ‘marry traditional Asian knowledge with modern science to create our proprietary, patent-pending M²CBD formula'.

They utilize functional mushrooms and high-quality CBD to enhance their formulas. 

The experts at the biotech company say that they will complete the feasibility study phase by 2023 and will lead to the next stage which will develop the drug in collaboration with a large pharmaceutical company via FDA approval. 

The biotech company plans to test the active mechanism of killing the cancerous cells by the extracts, including the combined anti-cancer efficacy of the fungus and cannabinoids together, in cells and animals.

Elhanan Shaked, CEO at Cannabotech said: “We have completed a significant milestone on the way to developing the botanical drug for pancreatic cancer. 

“This is another step that brings us closer to the great vision we set for ourselves and investors about three years ago. 

Alamy

“I am convinced that we will continue to meet the deadlines and that within 12 months, we will complete the feasibility stage and work for development cooperation with a large pharmaceutical company vis-à-vis the FDA."

According to cancer.org.au an estimated 4,261 cases of pancreatic cancer were reported in Australia in 2021.

The five-year survival rate for the cancer is only 11%, which makes Cannabotech’s discovery and recent research even more essential.

Alamy